89bio: New Positive Long-Term Data from Phase 2b Trial of Pegozafermin in NASH

 Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and fibrosis in NASH patients with fibrosis stage F2-F3—

—Subgroups of patients treated with pegozafermin on background GLP-1-based therapies and patients with compensated cirrhosis (F4) each showed robust benefits at week 48—

—Pegozafermin continued to demonstrate a favorable safety and tolerability profile consistent with previously reported data—

https://www.biospace.com/article/releases/89bio-announces-new-positive-long-term-data-from-the-enliven-phase-2b-trial-of-pegozafermin-in-patients-with-nonalcoholic-steatohepatitis-nash-/